Caris Life Sciences, Inc. (CAI) Financial Analysis & Valuation | Quarter Chart
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's mol... more
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling ... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $9.05B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | David Dean Halbert |
| IPO Date | 2025-06-18 | CAGR | 13.71% |
| Employees | 1,846 | Website | www.carislifesciences.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.01% | Total Yield | 0.01% |
CAI chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $8.19B | P/E | 89.91 | Forward P/E | 86.04 | PEG | — |
| P/S | 150735042.08 | P/B | 252933965.28 | P/CF | 742779774.45 | P/FCF | 1020537600.38 |
| Sales | $989.61M | Sales 1Y | 85.37% | Sales 3Y | 229.98% | Sales 5Y | 120.98% |
| EPS | $0.36 | EPS 1Y | -112.69% | EPS 3Y | -90.23% | EPS 5Y | -91.33% |
| Sales QoQ | 21.99% | EPS QoQ | 27.78% | Sales QoQ Avg | 12.6% | EPS QoQ Avg | 16.05% |
| Gross Margin | 69.66% | Operating Margin | 15.49% | Profit Margin | 10.62% | ROCE | 14.76% |
| ROA | 9% | ROE | 19% | Altman Z Score | 7.48 | Piotroski Score | 5 |
| Current Ratio | 5.53 | Quick Ratio | 4.88 | Cash Ratio | 3.61 | Op. CF Ratio | 0.32 |
| Debt/Equity | 0.76 | Debt/Assets | 0.37 | Lt Debt/Equity | 0.75 | Lt Debt/Cap. | 0.4 |
| Intrst Cov. | 3.27 | Inventory Turnover | 2.43 | Asset Turnover | 0.8 | Receivables Turnover | 8.47 |
| Enterprise Value | $8.19B | P/E Ratio | 89.91 |
| Forward P/E | 86.04 | PEG Ratio | — |
| P/S Ratio | 150735042.08 | P/B Ratio | 252933965.28 |
| P/CF Ratio | 742779774.45 | P/FCF Ratio | 1020537600.38 |
| EPS | $0.36 | EPS Growth 1Y | -112.69% |
| EPS Growth 3Y | -90.23% | EPS Growth 5Y | -91.33% |
| Revenue Growth 1Y | 85.37% | Gross Margin | 69.66% |
| Operating Margin | 15.49% | Profit Margin | 10.62% |
| ROE | 19% | ROA | 9% |
| ROCE | 14.76% | Current Ratio | 5.53 |
| Quick Ratio | 4.88 | Cash Ratio | 3.61 |
| Debt/Equity | 0.76 | Interest Coverage | 3.27 |
| Altman Z Score | 7.48 | Piotroski Score | 5 |
Caris Life Sciences, Inc. (CAI) valuation & financials
Caris Life Sciences, Inc. (CAI) has a market capitalization of $9.05B and trades at a price-to-earnings ratio of 89.9. It operates in the Healthcare sector (Biotechnology).
Caris Life Sciences, Inc.'s revenue grew +85.4% over the last year.
Caris Life Sciences, Inc.'s next earnings report is scheduled for November 4, 2026 after market close (provider scheduled date); analysts estimate EPS of $0.03. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)